Insider Selling: Kalaris Therapeutics (NASDAQ:KLRS) CAO Sells 1,915 Shares of Stock

Kalaris Therapeutics Inc. (NASDAQ:KLRS) CAO Brett Hagen sold 1,915 shares of the company’s stock in a transaction on Friday, March 20th. The shares were sold at an average price of $6.72, for a total value of $12,868.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Kalaris Therapeutics Stock Down 1.1%

KLRS traded down $0.07 during trading on Monday, reaching $6.50. 41,026 shares of the company’s stock were exchanged, compared to its average volume of 65,230. Kalaris Therapeutics Inc. has a fifty-two week low of $2.14 and a fifty-two week high of $12.26. The business has a 50 day moving average price of $9.34 and a 200 day moving average price of $7.34. The company has a market capitalization of $149.05 million, a P/E ratio of -1.54 and a beta of -0.13.

Kalaris Therapeutics (NASDAQ:KLRS) last announced its quarterly earnings data on Tuesday, March 17th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.12.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on KLRS shares. Citigroup reissued an “outperform” rating on shares of Kalaris Therapeutics in a research report on Thursday, December 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kalaris Therapeutics in a research note on Monday, December 29th. Wall Street Zen raised Kalaris Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Finally, Chardan Capital initiated coverage on Kalaris Therapeutics in a research report on Tuesday, December 23rd. They set a “buy” rating and a $19.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

Institutional Trading of Kalaris Therapeutics

Large investors have recently made changes to their positions in the business. Nano Cap New Millennium Growth Fund L P bought a new position in Kalaris Therapeutics in the 4th quarter worth approximately $34,000. Barclays PLC bought a new position in Kalaris Therapeutics in the 4th quarter valued at $51,000. Johnson Financial Group Inc. bought a new position in Kalaris Therapeutics in the 3rd quarter valued at $58,000. Keel Point LLC acquired a new stake in shares of Kalaris Therapeutics in the 4th quarter valued at $86,000. Finally, XTX Topco Ltd bought a new stake in shares of Kalaris Therapeutics during the fourth quarter worth $92,000. Institutional investors own 66.05% of the company’s stock.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.